Skip to content
Screener

Avalo Therapeutics AVTX Business Segments — Other

Similar metrics at other companies

KOR
KOREReportable Segment — Other
-$487K-276%
Butterfly Network logo
BFLYReportable segment — Other
$3.59M+80.6%
Trinet Group logo
TNETReportable Segment — Other
$14M+1,300%
NSA
NSAReportable Segment — Other
$3.1M-30.8%
LPR
LPROReportable Segment — Other
$2.27M+31.8%
Customers Bancorp logo
CUBIReportable Segment — Other
$10.91M+39.3%

Other financials

Income statement

See full
Revenue$59.0K-69.3%
Gross profit$963.0K+8,855%
Operating income-$31.5M-63.2%
Net income-$36.4M-75.1%
EPS (diluted)-$0.83+56.8%

Balance sheet

See full
Cash & equivalents$85.6M+101%
Total debt$242.0K-64.4%
Total equity$448.7M+329%
Total assets$490.8M+288%

Cash flow

See full
Operating cash flow-$20.0M-75.5%
CapEx-
Free cash flow-$15.0M-444%

Valuation

See full
Market cap$982.5M+908%
Enterprise value$897.13M+1,512%

Profitability

See full
Gross margin182%+176pp
Operating margin-15,536.1%-17,275pp
Net margin-7,965.8%-10,750pp
FCF margin-11,123.8%-13,374pp

Returns & leverage

See full
Return on equity-36.3%
Debt / equity0.0×
Current ratio19.3×+6.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherExpenses.

The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:03 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001534120-26-000049
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Clinical expenses3,7127,2159,34411,065
CMC expenses5,0683,2669,1945,245
License and milestone expenses10,00010,000
Internal expenses:
Salaries, benefits and related costs2,6302,1815,2164,030
Stock-based compensation expense1,6801,1162,9232,418
Other79117149175
$23,418$14,074$37,466$23,195

Item 1. Financial Statements.

FAQ

What is Avalo Therapeutics's business segments — other?
Avalo Therapeutics (AVTX) reported business segments — other of $79K in Q2 2026.
How has Avalo Therapeutics's business segments — other changed year-over-year?
Avalo Therapeutics's business segments — other decreased by 32.5% year-over-year, from $117K to $79K.
What is the long-term trend for Avalo Therapeutics's business segments — other?
Over 2 years (2023 to 2025), Avalo Therapeutics's business segments — other has grown at a 4.1% compound annual growth rate (CAGR), from $226K to $245K.
What does business segments — other mean?
Captures miscellaneous operational expenses that do not fall into primary categories like clinical, nonclinical, or personnel costs. These expenditures typically include general administrative support, facility overhead, or minor project-specific costs. Monitoring this category helps identify unexpected or ancillary costs that may impact the overall segment budget.

Ask your AI about Avalo Therapeutics's business segments — other.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude